Shanghai Hile Bio-tech Working Capital to Net Assets Ratio
Shanghai Hile Bio-tech working capital to net assets ratio. Shanghai Hile Bio-tech (603718) has a Working Capital to Net Assets ratio of 38.5% as of June 2026. Working capital of CN¥373.75 Million (current assets of CN¥600.82 Million minus current liabilities of CN¥227.07 Million) is measured against net assets of CN¥971.57 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 603718 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shanghai Hile Bio-tech (2011–2025)
Working capital to net assets ratio of Shanghai Hile Bio-tech from 2011 to 2025. This chart shows how Shanghai Hile Bio-tech's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 38.5%, reflecting working capital of CN¥373.75 Million against net assets of CN¥971.57 Million CNY. See how many days can Shanghai Hile Bio-tech fund operations to measure how many days the company can operate on defensive assets alone.
Shanghai Hile Bio-tech Working Capital to Net Assets Ratio by Year (2011–2025)
Shanghai Hile Bio-tech working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Hile Bio-tech from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Shanghai Hile Bio-tech.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 54.1% | CN¥484.30 Million | CN¥895.97 Million | CN¥595.84 Million | CN¥111.54 Million | ▲ +19.3 pp |
| 2024 | 34.7% | CN¥591.53 Million | CN¥1.70 Billion | CN¥691.77 Million | CN¥100.25 Million | ▲ +22.3 pp |
| 2023 | 12.4% | CN¥145.51 Million | CN¥1.17 Billion | CN¥562.55 Million | CN¥417.04 Million | ▼ -18.6 pp |
| 2022 | 31.0% | CN¥344.28 Million | CN¥1.11 Billion | CN¥665.03 Million | CN¥320.75 Million | ▲ +0.0 pp |
| 2021 | 30.9% | CN¥305.48 Million | CN¥987.19 Million | CN¥975.44 Million | CN¥669.96 Million | ▲ +20.3 pp |
| 2020 | 10.7% | CN¥102.48 Million | CN¥962.20 Million | CN¥742.49 Million | CN¥640.01 Million | ▼ -6.0 pp |
| 2019 | 16.7% | CN¥165.50 Million | CN¥992.57 Million | CN¥805.84 Million | CN¥640.34 Million | ▲ +4.0 pp |
| 2018 | 12.7% | CN¥130.15 Million | CN¥1.03 Billion | CN¥787.47 Million | CN¥657.31 Million | ▼ -20.9 pp |
| 2017 | 33.6% | CN¥361.21 Million | CN¥1.07 Billion | CN¥818.47 Million | CN¥457.27 Million | ▼ -23.0 pp |
| 2016 | 56.6% | CN¥569.15 Million | CN¥1.01 Billion | CN¥828.52 Million | CN¥259.38 Million | ▼ -14.2 pp |
| 2015 | 70.8% | CN¥682.02 Million | CN¥963.31 Million | CN¥787.99 Million | CN¥105.97 Million | ▲ +16.1 pp |
| 2014 | 54.7% | CN¥305.41 Million | CN¥558.50 Million | CN¥352.53 Million | CN¥47.12 Million | ▼ -3.5 pp |
| 2013 | 58.2% | CN¥291.26 Million | CN¥500.66 Million | CN¥354.41 Million | CN¥63.15 Million | ▲ +5.6 pp |
| 2012 | 52.6% | CN¥246.08 Million | CN¥467.89 Million | CN¥309.88 Million | CN¥63.80 Million | ▲ +11.2 pp |
| 2011 | 41.4% | CN¥167.81 Million | CN¥405.74 Million | CN¥244.96 Million | CN¥77.15 Million | — |